Thibault Goulvent1,2, Isabelle Ray-Coquard3, Stéphane Borel1, Véronique Haddad4, Mojgan Devouassoux-Shisheboran5, Marie-Cecile Vacher-Lavenu6, Eric Pujade-Laurraine7, Ariel Savina8, Denis Maillet3, Germain Gillet1, Isabelle Treilleux4, Ruth Rimokh1. 1. U1052 Inserm, UMR CNRS 5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Centre Léon Bérard, Lyon, France. 2. Institut Roche de Recherche et Médecine Translationnelle, Boulogne Billancourt, France. 3. Department of Medical Oncology, Université de Lyon, Centre Léon Bérard, Lyon, France. 4. Pathology Department, Centre Léon Bérard, Lyon, France. 5. Pathology Department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France. 6. Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris, France. 7. Hôtel-Dieu, Assistance Publique Hôpitaux de Paris, Paris, France. 8. RocheSAS Scientific Partnerships, Boulogne Billancourt, France.
Abstract
AIMS: FOXL2 mutation has been consistently identified in adult granulosa cell tumours (A-GCTs). DICER1 mutations have been described predominantly in Sertoli-Leydig cell tumours (SLCTs). The prognostic implication of these mutations remains uncertain, as moderately sized studies have yielded variable outcomes. Our aim was to determine the implications of DICER1 and FOXL2 mutations in 156 ovarian sex cord-stromal tumours (SCSTs). METHODS AND RESULTS: FOXL2 mutations were found in 94% of pathologically confirmed A-GCTs (95/101), in one of eight juvenile granulosa cell tumours (J-GCTs), and in two of 19 SLCTs. DICER1 mutations in the RNase IIIb domain were found in six of 19 SLCTs, two of eight J-GCTs, and one of 12 undifferentiated SCSTs (Und-SCSTs). Comparison of DICER1-mutated SLCTs with DICER1-non-mutated SLCTs showed that patient age at diagnosis was lower and oestrogen receptor expression was more frequent in DICER1-mutated tumours. With a median follow-up of 22 months, two of five DICER1-mutated SLCTs relapsed, in contrast to none of eight DICER1-non-mutated tumours. CONCLUSIONS: Our results suggest that, in contrast to FOXL2 mutations in A-GCT, DICER1 mutations in SLCT might be more useful for prognosis than for diagnosis. However, study of a larger cohort of patients is necessary to establish this. Identification of genetic alterations in SCST offers promising therapeutic options.
AIMS: FOXL2 mutation has been consistently identified in adult granulosa cell tumours (A-GCTs). DICER1 mutations have been described predominantly in Sertoli-Leydig cell tumours (SLCTs). The prognostic implication of these mutations remains uncertain, as moderately sized studies have yielded variable outcomes. Our aim was to determine the implications of DICER1 and FOXL2 mutations in 156 ovarian sex cord-stromal tumours (SCSTs). METHODS AND RESULTS:FOXL2 mutations were found in 94% of pathologically confirmed A-GCTs (95/101), in one of eight juvenile granulosa cell tumours (J-GCTs), and in two of 19 SLCTs. DICER1 mutations in the RNase IIIb domain were found in six of 19 SLCTs, two of eight J-GCTs, and one of 12 undifferentiated SCSTs (Und-SCSTs). Comparison of DICER1-mutated SLCTs with DICER1-non-mutated SLCTs showed that patient age at diagnosis was lower and oestrogen receptor expression was more frequent in DICER1-mutated tumours. With a median follow-up of 22 months, two of five DICER1-mutated SLCTs relapsed, in contrast to none of eight DICER1-non-mutated tumours. CONCLUSIONS: Our results suggest that, in contrast to FOXL2 mutations in A-GCT, DICER1 mutations in SLCT might be more useful for prognosis than for diagnosis. However, study of a larger cohort of patients is necessary to establish this. Identification of genetic alterations in SCST offers promising therapeutic options.
Authors: Victoria Cluzet; Marie M Devillers; Florence Petit; Stéphanie Chauvin; Charlotte M François; Frank Giton; Catherine Genestie; Nathalie di Clemente; Joëlle Cohen-Tannoudji; Céline J Guigon Journal: Oncogene Date: 2019-11-19 Impact factor: 9.867
Authors: Niamh Conlon; Anne M Schultheis; Salvatore Piscuoglio; Annacarolina Silva; Esther Guerra; Carmen Tornos; Victor E Reuter; Robert A Soslow; Robert H Young; Esther Oliva; Britta Weigelt Journal: Mod Pathol Date: 2015-10-02 Impact factor: 7.842
Authors: Riccardo Di Fiore; Sherif Suleiman; Francesca Pentimalli; Sharon A O'Toole; John J O'Leary; Mark P Ward; Neil T Conlon; Maja Sabol; Petar Ozretić; Ayse Elif Erson-Bensan; Nicholas Reed; Antonio Giordano; C Simon Herrington; Jean Calleja-Agius Journal: Int J Mol Sci Date: 2021-04-07 Impact factor: 5.923
Authors: Anna Maria Caroleo; Maria Antonietta De Ioris; Luigi Boccuto; Iside Alessi; Giada Del Baldo; Antonella Cacchione; Emanuele Agolini; Martina Rinelli; Annalisa Serra; Andrea Carai; Angela Mastronuzzi Journal: Front Oncol Date: 2021-01-21 Impact factor: 6.244
Authors: Asaf Maoz; Koji Matsuo; Marcia A Ciccone; Shinya Matsuzaki; Maximilian Klar; Lynda D Roman; Anil K Sood; David M Gershenson Journal: Cancers (Basel) Date: 2020-05-29 Impact factor: 6.639